Top

Published in:

Open Access 01-04-2022 | Acromegaly

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States

Authors: Maria Fleseriu, Ariel Barkan, Maria del Pilar Schneider, Yannis Darhi, Amicie de Pierrefeu, Antonio Ribeiro-Oliveira Jr., Stephan Petersenn, Sebastian Neggers, Shlomo Melmed

Published in: Pituitary | Issue 2/2022

Abstract

Purpose

Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.

Methods

Administrative claims data were obtained from the IBM® MarketScan® database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.

Results

Overall, 1175 patients with acromegaly and 5875 matched patients without acromegaly were included. Patients with acromegaly had significantly more comorbidities and were prescribed concomitant medications more so than patients without acromegaly. In the acromegaly and control cohorts, respectively, 67.6% and 48.4% of patients had cardiovascular disorders, the most prevalent comorbidities, and 89.0% and 68.3% were prescribed > 3 concomitant medications (p < 0.0001). Hypopituitarism and hypothalamic disorders, sleep apnea, malignant neoplasms and cancer, and arthritis and musculoskeletal disorders were also highly prevalent in the acromegaly cohort. A moderate, positive correlation (Spearman correlation coefficient 0.60) was found between number of comorbidities and number of concomitant medications in the acromegaly cohort.

Conclusion

Compared with patients without acromegaly, patients with acromegaly have significantly more comorbidities and are prescribed significantly more concomitant medications. Physicians should consider the number and type of ongoing medications for individual patients before prescribing additional acromegaly treatments.

Available only for authorised users

Fleseriu M, Barkan A, del Schneider MP, Darhi Y, de Pierrefeu A, Munoz K, Ribeiro-Oliveira A, Melmed S (2021) The pharmacological burden of comorbidities in acromegaly. J Endocr Soc 5(Suppl 1):A649–A650. https://doi.org/10.1210/jendso/bvab048.1324CrossRefPubMedCentral

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH (2014) Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700CrossRef

Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382(10):937–950. https://doi.org/10.1056/NEJMra1810772CrossRefPubMed

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561. https://doi.org/10.1038/s41574-018-0058-5CrossRefPubMedPubMedCentral

Vila G, Luger A, van der Lely AJ, Neggers S, Webb SM, Biller BMK, Valluri S, Hey-Hadavi J (2020) Hypertension in acromegaly in relationship to biochemical control and mortality: global ACROSTUDY outcomes. Front Endocrinol (Lausanne) 11:577173. https://doi.org/10.3389/fendo.2020.577173CrossRef

Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N (2017) Epidemiology of acromegaly: review of population studies. Pituitary 20(1):4–9. https://doi.org/10.1007/s11102-016-0754-xCrossRefPubMed

AlDallal S (2018) Acromegaly: a challenging condition to diagnose. Int J Gen Med 11:337–343. https://doi.org/10.2147/ijgm.S169611CrossRefPubMedPubMedCentral

Brue T, Castinetti F (2016) The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis 11(1):135. https://doi.org/10.1186/s13023-016-0516-xCrossRefPubMedPubMedCentral

Martín-Rodríguez JF, Madrazo-Atutxa A, Venegas-Moreno E, Benito-López P, Gálvez MÁ, Cano DA, Tinahones FJ, Torres-Vela E, Soto-Moreno A, Leal-Cerro A (2013) Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PLoS ONE 8(4):e60041. https://doi.org/10.1371/journal.pone.0060041CrossRefPubMedPubMedCentral

10.

Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93(1):61–67. https://doi.org/10.1210/jc.2007-1191CrossRefPubMed

11.

Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case–control study. J Clin Endocrinol Metab 88(7):3196–3201. https://doi.org/10.1210/jc.2002-021099CrossRefPubMed

12.

Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Investig 119(11):3189–3202. https://doi.org/10.1172/jci39375CrossRefPubMedPubMedCentral

13.

Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268–332. https://doi.org/10.1210/er.2018-00115CrossRefPubMed

14.

Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305–310. https://doi.org/10.1530/eje-07-0697CrossRefPubMed

15.

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgz096CrossRefPubMedPubMedCentral

16.

McCabe J, Ayuk J, Sherlock M (2016) Treatment factors that influence mortality in acromegaly. Neuroendocrinology 103(1):66–74. https://doi.org/10.1159/000375163CrossRefPubMed

17.

Whittington M, Munoz K, Whalen J, Ribeiro-Oliveira A Jr, Campbell J (2021) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res 59:101389. https://doi.org/10.1016/j.ghir.2021.101389CrossRefPubMed

18.

Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7CrossRefPubMed

19.

Burton T, Le Nestour E, Bancroft T, Neary M (2013) Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3):354–362. https://doi.org/10.1007/s11102-012-0432-6CrossRefPubMed

20.

Maia B, Kasuki L, Gadelha MR (2020) Novel therapies for acromegaly. Endocr Connect 9(12):R274–R285. https://doi.org/10.1530/EC-20-0433CrossRefPubMedPubMedCentral

21.

Sabbatini M, Garofalo G, Borrelli S, Vitale S, Torino M, Capone D, Russo L, Pisani A, Carrano R, Gallo R, Federico S (2014) Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 8:73–81. https://doi.org/10.2147/ppa.s54922CrossRefPubMedPubMedCentral

22.

Blüher M, Kurz I, Dannenmaier S, Dworak M (2015) Pill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes 33(2):55. https://doi.org/10.2337/diaclin.33.2.55CrossRefPubMedPubMedCentral

23.

Farrell B, French Merkley V, Ingar N (2013) Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J 146(5):262–269. https://doi.org/10.1177/1715163513500208CrossRef

24.

Mohammed MA, Moles RJ, Chen TF (2016) Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open 6(2):e010035. https://doi.org/10.1136/bmjopen-2015-010035CrossRefPubMedPubMedCentral

25.

van Merode T, van de Ven K, van den Akker M (2018) Patients with multimorbidity and their treatment burden in different daily life domains: a qualitative study in primary care in the Netherlands and Belgium. J Comorbidity 8(1):9–15. https://doi.org/10.15256/joc.2018.8.119CrossRef

26.

Khandeparkar A, Rataboli PV (2017) A study of harmful drug–drug interactions due to polypharmacy in hospitalized patients in Goa Medical College. Perspect Clin Res 8(4):180–186. https://doi.org/10.4103/picr.PICR_132_16CrossRefPubMedPubMedCentral

27.

Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave J-P, Cavassini M, Bernasconi E, Calmy A (2010) Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antivir Ther 15(3):413. https://doi.org/10.3851/imp1540CrossRefPubMed

28.

Homayun B, Lin X, Choi H-J (2019) Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 11(3):129. https://doi.org/10.3390/pharmaceutics11030129CrossRefPubMedCentral

29.

Kim H, Park H, Lee SJ (2017) Effective method for drug injection into subcutaneous tissue. Sci Rep 7(1):9613–9613. https://doi.org/10.1038/s41598-017-10110-wCrossRefPubMedPubMedCentral

30.

Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682. https://doi.org/10.1093/aje/kwq433CrossRefPubMed

31.

Python Software Foundation (n.d.) Python language reference. http://www.python.org. Accessed 7 Dec 2021

32.

Kamusheva M, Vandeva S, Mitov K, Rusenova Y, Elenkova A, Zacharieva S, Mitkova Z, Tachkov K, Dimitrova M, Doneva M, Tcharaktchiev D, Petrova G (2020) New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. Front Public Health 8:147. https://doi.org/10.3389/fpubh.2020.00147CrossRefPubMedPubMedCentral

33.

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diallo AM, Hulting A-L, Ferone D, Hana V Jr, Filipponi S, Sievers C, Nogueira C, Fajardo-Montañana C, Carvalho D, Hana V, Stalla GK, Jaffrain-Réa M-L, Delemer B, Colao A, Brue T, Neggers SJCMM, Zacharieva S, Chanson P, Beckers A (2017) Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505–518. https://doi.org/10.1530/ERC-17-0253CrossRefPubMedPubMedCentral

34.

Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States From 1999–2012. JAMA 314(17):1818–1831. https://doi.org/10.1001/jama.2015.13766CrossRefPubMedPubMedCentral

35.

Bushra R, Aslam N, Khan AY (2011) Food–drug interactions. Oman Med J 26(2):77–83. https://doi.org/10.5001/omj.2011.21CrossRefPubMedPubMedCentral

36.

FDA (2008) Prescribing information: glucotrol—glipzide tablet. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017783s019lbl.pdf. Accessed 7 Dec 2021

37.

Colucci P, Yue CS, Ducharme M, Benvenga S (2013) A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol 9(1):40–47. https://doi.org/10.17925/EE.2013.09.01.40CrossRefPubMedPubMedCentral

38.

Wiesner A, Szuta M, Galanty A, Paśko P (2021) Optimal dosing regimen of osteoporosis drugs in relation to food intake as the key for the enhancement of the treatment effectiveness—a concise literature review. Foods (Basel Switz) 10(4):720. https://doi.org/10.3390/foods10040720CrossRef

39.

Wedemeyer R-S, Blume H (2014) Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 37(4):201–211. https://doi.org/10.1007/s40264-014-0144-0CrossRefPubMedPubMedCentral

40.

FDA (2020) Highlights of prescribing information. In: MYCAPSSA (octreotide) delayed-release capsules, for oral use. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208232s000lbl.pdf. Accessed 7 Dec 2021

41.

Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1):117. https://doi.org/10.1186/s12902-020-00595-4CrossRefPubMedPubMedCentral

42.

Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH, Haviv A, Mathias SD (2020) An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary 23(4):347–358. https://doi.org/10.1007/s11102-020-01038-yCrossRefPubMedPubMedCentral

43.

Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64(2):209–214. https://doi.org/10.1111/j.1365-2265.2006.02450.xCrossRef

44.

Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt LV, Eimicke T, Olshan JS (2017) Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab 102(7):2349–2355. https://doi.org/10.1210/jc.2017-00359CrossRefPubMed

45.

NHS (2018) Can small volume intramuscular injections be given to patients taking oral anticoagulants? NHS. https://www.sps.nhs.uk/wp-content/uploads/2018/09/UKMI_QA_IM-inj-anticoag_partial-update_Sept2018.pdf. Accessed 7 Dec 2021

46.

Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107(12):1692–1711. https://doi.org/10.1161/01.CIR.0000063575.17904.4ECrossRefPubMed

47.

Alpert JS (2019) Take-home messages from the recently updated AHA/ACC guidelines for atrial fibrillation. Am J Med 132(12):1363–1364. https://doi.org/10.1016/j.amjmed.2019.07.021CrossRefPubMed

48.

Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH (2021) 2020 ACC Expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol 77(5):629–658. https://doi.org/10.1016/j.jacc.2020.09.011CrossRefPubMed

49.

Petersenn S, Houchard A, del Pilar Schneider M, Ribeiro-Oliveira A Jr, Neggers S (2021) Use of oral concomitant medications in patients with acromegaly. J Endocr Soc 5(Suppl 1):A528–A529. https://doi.org/10.1210/jendso/bvab048.1076CrossRefPubMedCentral

50.

Brue T, Lindberg A, van der Lely JA, Akerblad AC, Koltowska-Häggström M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-Hübner C (2019) Diabetes in patients with acromegaly treated with pegvisomant: observations from ACROSTUDY. Endocrine 63(3):563–572. https://doi.org/10.1007/s12020-018-1792-0CrossRefPubMed

Title: Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
Authors: Maria Fleseriu
Ariel Barkan
Maria del Pilar Schneider
Yannis Darhi
Amicie de Pierrefeu
Antonio Ribeiro-Oliveira Jr.
Stephan Petersenn
Sebastian Neggers
Shlomo Melmed
Publication date: 01-04-2022
Publisher: Springer US
Keywords: Acromegaly
Anticoagulant
Published in: Pituitary / Issue 2/2022
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-021-01198-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay

Characterization of a paradoxical post-operative increase in serum cortisol in Cushing disease

Hypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome

Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length

Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly

Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials